Table 1.

Demographics and characteristics of the participants.

	PPMI cohort				GSH cohort
	Controls	sPD	LRRK2	GBA	Controls	sPD
	(n = 213)	(n = 367)	(n = 72)	(n = 39)	(n = 71)	(n = 38)
Age (years)	60.9 ± 11.3	60.9 ± 11.3	62.0 ± 8.6	61.5 ± 11.2	59.7 ± 10.3	62.3 ± 9.7
Female subjects	73 (34.3%)	127 (34.6%)	38 (52.8%)*†	17 (43.6%)	39 (54.9%)	20 (52.6%)
AAO (years)	n.a.	60.7 [13.6]	59.8 [11.3]	57.6 [15.4]	n.a.	59.7 [16.1]
Disease duration (years)	n.a.	1.5 [1.6]	3.5 [3.3]†	3.3[4.2]†	n.a.	1.1 [1.3]
MDS-UPDRS III	n.a.	20.8 ± 8.7	20.9 ± 9.2	26.6 ± 11.2†‡	n.a.	24.9 ± 9.1
H&Y stage (I/II/III)(%)	n.a.	163/204/0 (44.4/55.6/0)	11/26/4† (26.8/63.4/9.8)	11/20/1† (34.4/62.5/3.1)	n.a.	n.a.
GRS	5.90 ± 0.63	6.19 ± 0.65*	n.a	n.a	n.a.	n.a.
Striatal SBRs
CN, more affected	2.97 ± 0.61 (averaged)	1.83 ± 0.53*	1.78 ± 0.50*	1.70 ± 0.72*	5.84 ± 1.24 (averaged)	4.35 ± 1.30*
CN, less affected	2.97 ± 0.61 (averaged)	2.14 ± 0.59*	1.96 ± 0.59*†	1.94 ± 0.75*†	5.84 ± 1.24 (averaged)	4.76 ± 1.39*
PUT, more affected	2.13 ± 0.55 (averaged)	0.66 ± 0.24*	0.63 ± 0.21*	0.67 ± 0.43*	8.07 ± 1.27 (averaged)	3.75 ± 1.07*
PUT, less affected	2.13 ± 0.55 (averaged)	0.98 ± 0.37*	0.86 ± 0.30*†	0.89 ± 0.49*	8.07 ± 1.27 (averaged)	4.80 ± 1.22*

Mean ± SD for variables with Gaussian distribution. Median [interquartile range] for variables showing non-Gaussian distribution. Abbreviations: PPMI Parkinson’s Progression Markers Initiative, GSH Gangnam Severance Hospital, AAO age at onset, MDS-UPDRS III Movement Disorder Society sponsored Unified Parkinson’s Disease Rating Scales part III, total scores, GRS genetic risk scores, SBRs specific binding ratios, CN caudate nucleus, PUT putamen, *significant difference with control subjects, ^†significant difference with sPD group, ^‡significant difference between GBA and LRRK2 group, n.a. not available.